Maite Gorostegui
Hospital Sant Joan de Déu Barcelona(ES)
Publications by Year
Research Areas
Neuroblastoma Research and Treatments, Cancer, Hypoxia, and Metabolism, Neuroendocrine Tumor Research Advances, Childhood Cancer Survivors' Quality of Life, Lung Cancer Research Studies
Most-Cited Works
- → Initial report on Spanish pediatric oncologic, hematologic, and post stem cell transplantation patients during SARS‐CoV‐2 pandemic(2020)39 cited
- → Naxitamab combined with granulocyte‐macrophage colony‐stimulating factor as consolidation for high‐risk neuroblastoma patients in complete remission(2021)29 cited
- → Prognostic value of patient‐derived xenograft engraftment in pediatric sarcomas(2021)27 cited
- → Early Salvage Chemo-Immunotherapy with Irinotecan, Temozolomide and Naxitamab Plus GM-CSF (HITS) for Patients with Primary Refractory High-Risk Neuroblastoma Provide the Best Chance for Long-Term Outcomes(2023)23 cited
- → The Role of Autologous Stem-Cell Transplantation in High-Risk Neuroblastoma Consolidated by anti-GD2 Immunotherapy. Results of Two Consecutive Studies(2020)23 cited
- → Naxitamab Combined with Granulocyte-Macrophage Colony-Stimulating Factor as Consolidation for High-Risk Neuroblastoma Patients in First Complete Remission under Compassionate Use—Updated Outcome Report(2023)21 cited
- → How we approach the treatment of patients with high-risk neuroblastoma with naxitamab: experience from the Hospital Sant Joan de Déu in Barcelona, Spain(2022)16 cited
- → Clinical and Pathological Evidence of Anti-GD2 Immunotherapy Induced Differentiation in Relapsed/Refractory High-Risk Neuroblastoma(2021)14 cited
- → Naxitamab-based chemoimmunotherapy for resistant high-risk neuroblastoma: Results of "HITS" phase II study.(2022)11 cited
- → Novel infusion strategy reduces severe adverse events caused by the anti-GD2 monoclonal antibody naxitamab(2023)10 cited